Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yubin Ge

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2010
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaChengzhi Xie, Holly Edwards, Xuelian Xu, et al.
Biochemical Pharmacology|August 21, 2023
Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanismsJenna L Carter, Yongwei Su, Xinan Qiao, et al.
Molecular Cancer Therapeutics|June 24, 2010
Telomerase as an important target of androgen signaling blockade for prostate cancer treatmentShuang Liu, Yanfeng Qi, Yubin Ge, et al.
Plos One|November 24, 2011
A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapyAna C Xavier, Holly Edwards, Alan A Dombkowski, et al.
Oncotarget|June 3, 2017
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancerChangwen Ning, Min Liang, Shuang Liu, et al.
Scientific Reports|February 9, 2017
Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cellsJun Ma, Xinyu Li, Yongwei Su, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemiaDaniel A Luedtke, Yongwei Su, Jun Ma, et al.
Cancer Cell|November 14, 2018
A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia PathogenesisAndrew Volk, Kaiwei Liang, Praveen Suraneni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2016
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML CellsXiaojia Niu, Jianyun Zhao, Jun Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2019
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid LeukemiaJun Ma, Shoujing Zhao, Xinan Qiao, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2010
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaChengzhi Xie, Holly Edwards, Xuelian Xu, et al.
Biochemical Pharmacology|August 21, 2023
Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanismsJenna L Carter, Yongwei Su, Xinan Qiao, et al.
Molecular Cancer Therapeutics|June 24, 2010
Telomerase as an important target of androgen signaling blockade for prostate cancer treatmentShuang Liu, Yanfeng Qi, Yubin Ge, et al.
Plos One|November 24, 2011
A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapyAna C Xavier, Holly Edwards, Alan A Dombkowski, et al.
Oncotarget|June 3, 2017
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancerChangwen Ning, Min Liang, Shuang Liu, et al.
Scientific Reports|February 9, 2017
Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cellsJun Ma, Xinyu Li, Yongwei Su, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemiaDaniel A Luedtke, Yongwei Su, Jun Ma, et al.
Cancer Cell|November 14, 2018
A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia PathogenesisAndrew Volk, Kaiwei Liang, Praveen Suraneni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2016
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML CellsXiaojia Niu, Jianyun Zhao, Jun Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2019
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid LeukemiaJun Ma, Shoujing Zhao, Xinan Qiao, et al.
Pageof 14